StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research note released on Wednesday morning. The firm issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. The firm has a market cap of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a 1 year low of $0.00 and a 1 year high of $0.00.
About Genocea Biosciences
Recommended Stories
- Five stocks we like better than Genocea Biosciences
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 Momentum Trades for October With Ample Upside Ahead
- Stock Average Calculator
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- Retail Stocks Investing, Explained
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.